First-Line Treatment for Reactive Hepatitis C

Treatment Recommendations

The American Association for the Study of Liver Diseases recommends a pangenotypic direct-acting antiviral (DAA) regimen consisting of either sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8-12 weeks, depending on cirrhosis status and treatment history, for the first-line treatment of reactive hepatitis C 1
For patients with genotype 1 infection, the recommended first-line options include sofosbuvir/velpatasvir for 12 weeks, with a high SVR rate of 98% 2, 1
For patients with genotype 2 infection, sofosbuvir/velpatasvir for 12 weeks is a recommended first-line option 3, 1
For patients with genotype 3 infection, sofosbuvir/velpatasvir for 12 weeks and sofosbuvir/daclatasvir for 12 weeks are recommended first-line options 3, 1

For patients with compensated cirrhosis, the same regimens as non-cirrhotic patients can be used, but treatment duration may need to be extended to 12 weeks for glecaprevir/pibrentasvir 1
For patients with decompensated cirrhosis, sofosbuvir/velpatasvir plus ribavirin for 12 weeks is a recommended treatment option 4
In HIV-coinfected patients, the same HCV treatment regimens can be used as in patients without HIV infection, with dose adjustments needed in case of interactions with antiretroviral drugs 1
The dose of daclatasvir must be adjusted to 30 mg in HIV-coinfected patients receiving ritonavir- or cobicistat-boosted atazanavir or cobicistat-boosted elvitegravir, and to 90 mg in HIV-coinfected patients receiving efavirenz 3

Monitoring HCV RNA levels at baseline, weeks 4 and 12 during treatment, at the end of treatment, and 12 weeks after completion is recommended to assess sustained virologic response (SVR) 5
For patients with cirrhosis, continued monitoring for hepatocellular carcinoma with ultrasound every 6 months is recommended, even after achieving SVR 1

Modern DAA regimens achieve SVR rates exceeding 95% in most patient populations, with the combination of sofosbuvir/velpatasvir showing SVR rates of 98% in genotype 1 infection 2
Treatment success is defined as achieving sustained virologic response (SVR), which means undetectable HCV RNA 12 weeks after treatment completion 1

Drug-drug interactions must be carefully evaluated before initiating DAA therapy, particularly in patients on multiple medications 2